3.00
-0.20 (-6.25%)
| Previous Close | 3.20 |
| Open | 3.20 |
| Volume | 1,221,440 |
| Avg. Volume (3M) | 1,050,564 |
| Market Cap | 175,778,096 |
| Price / Book | 8.44 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -3.04 |
| Current Ratio (MRQ) | 1.16 |
| Operating Cash Flow (TTM) | -142.86 M |
| Levered Free Cash Flow (TTM) | -102.50 M |
| Return on Assets (TTM) | -30.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Omeros Corporation | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.40% |
| % Held by Institutions | 47.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ingalls & Snyder Llc | 31 Mar 2025 | 3,977,813 |
| Corient Private Wealth Llc | 31 Mar 2025 | 720,422 |
| Nomura Holdings Inc | 31 Mar 2025 | 679,020 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 36.00 (D. Boral Capital, 1,100.00%) | Buy |
| Median | 22.50 (650.00%) | |
| Low | 9.00 (HC Wainwright & Co., 200.00%) | Buy |
| Average | 22.50 (650.00%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 30 Jun 2025 | 36.00 (1,100.00%) | Buy | 3.18 |
| 13 May 2025 | 36.00 (1,100.00%) | Buy | 4.43 | |
| HC Wainwright & Co. | 10 Jun 2025 | 9.00 (200.00%) | Buy | 3.88 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |